Clinical trial
A Phase I/II Multicenter Study of IY5511HCl in Philadelphia Chromosome Positive Chronic Myeloid Leukemia Patients Without Optimal Response or Tolerance to Bcr-Abl Tyrosine Kinase Inhibitors (Imatinib and/ or Dasatinib, Nilotinib)
NCT01602952 is registered in ClinicalTrials.gov with Il-Yang Pharm. Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Multicenter Study of IY5511HCl in Philadelphia Chromosome Positive Chronic Myeloid Leukemia Patients Without Optimal Response or Tolerance to Bcr-Abl Tyrosine Kinase Inhibitors (Imatinib and/ or Dasatinib, Nilotinib)
- Lead sponsor
- Il-Yang Pharm. Co., Ltd.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- July 31, 2008
- Completion date
- July 13, 2018
- Enrollment
- 85 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.